Logo image of PHGE

BIOMX INC (PHGE) Stock Price, Forecast & Analysis

USA - NYSE Arca - NYSEARCA:PHGE - US09090D5095 - Common Stock

2.61 USD
-0.03 (-1.14%)
Last: 1/15/2026, 8:07:24 PM

PHGE Key Statistics, Chart & Performance

Key Statistics
Market Cap3.99M
Revenue(TTM)N/A
Net Income(TTM)-18.57M
Shares1.53M
Float1.26M
52 Week High22.06
52 Week Low1.5
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-29.64
PEN/A
Fwd PEN/A
Earnings (Next)03-23
IPO2018-12-18
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
PHGE short term performance overview.The bars show the price performance of PHGE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 50 -50

PHGE long term performance overview.The bars show the price performance of PHGE in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of PHGE is 2.61 USD. In the past month the price increased by 68.39%. In the past year, price decreased by -82.09%.

BIOMX INC / PHGE Daily stock chart

PHGE Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to PHGE. When comparing the yearly performance of all stocks, PHGE is a bad performer in the overall market: 99.07% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

PHGE Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to PHGE. While PHGE seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PHGE Financial Highlights

Over the last trailing twelve months PHGE reported a non-GAAP Earnings per Share(EPS) of -29.64. The EPS increased by 43.62% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -48.8%
ROE -96.91%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)43.62%
Revenue 1Y (TTM)N/A

PHGE Forecast & Estimates

8 analysts have analysed PHGE and the average price target is 168.3 USD. This implies a price increase of 6348.28% is expected in the next year compared to the current price of 2.61.


Analysts
Analysts82.5
Price Target168.3 (6348.28%)
EPS Next Y-834.26%
Revenue Next YearN/A

PHGE Ownership

Ownership
Inst Owners32.01%
Ins Owners1.33%
Short Float %N/A
Short Ratio0.09

PHGE Latest News, Press Relases and Analysis

About PHGE

Company Profile

PHGE logo image Biomx Inc is a IL-based company operating in Biotechnology industry. BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The firm is focused on developing both natural and engineered phage therapies. The company develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The firm discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).

Company Info

BIOMX INC

22 Einstein St., Floor 4

Ness Ziona MARYLAND 7414002 IL

CEO: Jonathan Solomon

Employees: 52

PHGE Company Website

PHGE Investor Relations

Phone: 972723942377

BIOMX INC / PHGE FAQ

What does PHGE do?

Biomx Inc is a IL-based company operating in Biotechnology industry. BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The firm is focused on developing both natural and engineered phage therapies. The company develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The firm discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).


What is the stock price of BIOMX INC today?

The current stock price of PHGE is 2.61 USD. The price decreased by -1.14% in the last trading session.


Does BIOMX INC pay dividends?

PHGE does not pay a dividend.


What is the ChartMill technical and fundamental rating of PHGE stock?

PHGE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the market capitalization of PHGE stock?

BIOMX INC (PHGE) has a market capitalization of 3.99M USD. This makes PHGE a Nano Cap stock.